News

  1. SGD Pharma Expands Capacity Of Siliconized Glass Vials With The Announcement Of A New Siliconization Line At Its Center Of Excellence For Type I Glass In France 1/22/2024

    SGD Pharma, Global market leader in molded glass primary packaging solutions for the pharmaceutical industry, announces the opening of a new siliconization operation at its state-of-the-art Saint-Quentin Lamotte (SQLM) plant. The company enhances its already extensive range of in-house services by internalizing its glass siliconization offer, further ensuring responsiveness, security of supply and improved flexibility of vial sizes.

  2. Kindeva Drug Delivery Acquires Summit Biosciences, A Specialized Nasal Drug Development And Manufacturing Organization 1/18/2024

    Kindeva Drug Delivery (“Kindeva”), a global leader in drug-device combination products, announced today that it has acquired Summit Biosciences Inc. (“Summit”), an intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders.

  3. SGD Pharma Announces The Appointment Of Fabio Invernizzi, General Manager West Business Unit 1/17/2024

    SGD Pharma, global primary glass packaging leader, has announced the appointment of Fabio Invernizzi as its new General Manager of its West BU. The BU West includes SGD Pharma’s commercial activities for MEA, North and South America and our manufacturing footprint in Europe. Fabio joins the Group Executive Committee bringing over 15 years of experience in Commercial, Marketing and Business Development at a senior level for the life science industry. He joins SGD Pharma following his last position as Vice-President and EMEA BU Head of Capsules and Health Ingredients at Lonza. Prior to that role, Fabio led the Global Commercial & Business Development activities for the Capsules & Heath Ingredients Division at Lonza.

  4. SGD Pharma Defines 2024 Growth Strategy As It Strives For Market Leadership With Investment Achievements 1/8/2024

    SGD Pharma, announces its goal to become the global market leader in primary pharmaceutical glass packaging. CEO Olivier Rousseau explains that SGD Pharma intends to significantly grow in 2024, with a sustained and consistent approach to its commercial, innovation, industrial, sustainability, HR and M&A strategies.

  5. SGD Pharma Commits To Near-Term Science Based Targets Initiative As Part Of Sustainability Drive 11/7/2023

    SGD Pharma, the global market leader in molded glass packaging solutions for the pharmaceutical industry, announces its commitment to company-wide emissions reductions as part of its decarbonization strategy by joining the Science Based Targets initiative (SBTi).

  6. BD To Showcase Its Commitment To Drug Delivery And Packaging Innovation At CPhI 2023 Conference 10/18/2023
  7. SHL Medical And Lifecore Biomedical Enter Co-Marketing Partnership Agreement 10/17/2023

    The partnership allows the companies to provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.

  8. SGD Pharma Continues To Innovate With The Extension Of Its Ready-To-Use Sterinity Glass Vials For Parenteral Pharmaceutical Applications, Adding 10ml And 20ml To Its ISO Portfolio 10/11/2023

    Global market leader in molded glass packaging solutions for the pharmaceutical industry, SGD Pharma announces the latest expansion of its Sterinity range of Ready-To-Use (RTU) Type I molded glass vials. The launch of additional sizes 10H*ml and 20H ml in tray is advantageous to customers who will benefit from increased flexibility as a result of the extended portfolio.

  9. Ocular Therapeutix™ Announces Initiation Of Its First Pivotal Clinical Trial of OTX-TKI In Wet AMD 10/11/2023

    Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the Company’s axitinib intravitreal implant, for the treatment of wet age-related macular degeneration (wet AMD). OTX-TKI is also being developed for the treatment of diabetic retinopathy and other retinal diseases.

  10. Enable Injections Receives First U.S. Food And Drug Administration (FDA) Approval 10/2/2023

    Enable Injections, Inc. (“Enable”) today announced that the U.S. Food and Drug Administration (FDA) has approved the  EMPAVELI Injector (enFuse®) for the subcutaneous delivery of EMPAVELI® (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH). The EMPAVELI Injector is a compact, wearable injector designed to streamline the self-administration experience with minimal disruption to patients’ daily lives.